Latest Insider Transactions at Harpoon Therapeutics, Inc. (HARP)
This section provides a real-time view of insider transactions for Harpoon Therapeutics, Inc. (HARP). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Harpoon Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Harpoon Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 11
2024
|
Scott Dunseth Myers |
SELL
Sale (or disposition) back to the issuer
|
Direct |
22,665
-100.0%
|
-
|
|
Mar 11
2024
|
Luke Nathaniel Walker Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
135,000
-100.0%
|
-
|
|
Mar 11
2024
|
Ronald Hunt |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
10,000
-100.0%
|
-
|
|
Mar 11
2024
|
Ronald Hunt |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
1,859,169
-100.0%
|
-
|
|
Mar 11
2024
|
Ronald Hunt |
SELL
Sale (or disposition) back to the issuer
|
Direct |
13,224
-100.0%
|
-
|
|
Mar 11
2024
|
Lauren P Silvernail |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,000
-100.0%
|
-
|
|
Mar 11
2024
|
New Leaf Biopharma Opportunities Ii, L.P. |
SELL
Sale (or disposition) back to the issuer
|
Direct |
10,000
-100.0%
|
-
|
|
Mar 11
2024
|
New Leaf Biopharma Opportunities Ii, L.P. |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
395,783
-100.0%
|
-
|
|
Mar 11
2024
|
New Leaf Biopharma Opportunities Ii, L.P. |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,463,386
-100.0%
|
-
|
|
Mar 11
2024
|
Mark Chin |
SELL
Sale (or disposition) back to the issuer
|
Direct |
13,224
-100.0%
|
-
|
|
Mar 11
2024
|
Joseph S Bailes |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,000
-100.0%
|
-
|
|
Mar 11
2024
|
Julia Marie Eastland President and CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
269,381
-100.0%
|
-
|
|
Mar 11
2024
|
Julia Marie Eastland President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
31,250
+10.39%
|
-
|
|
Mar 11
2024
|
Frank J Lanza Principal Fin. & Acctng Ofc. |
SELL
Sale (or disposition) back to the issuer
|
Direct |
18,734
-100.0%
|
-
|
|
Mar 11
2024
|
Andrew R Robbins |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,000
-100.0%
|
-
|
|
Mar 11
2024
|
Jonathan G Drachman |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,415
-100.0%
|
-
|
|
Mar 11
2024
|
Merck & Co., Inc. |
BUY
Open market or private purchase
|
Indirect |
21,397,205
+100.0%
|
$492,135,715
$23.0 P/Share
|
|
Mar 08
2024
|
Ronald Hunt |
BUY
Grant, award, or other acquisition
|
Direct |
424
+3.11%
|
-
|
|
Mar 08
2024
|
Mark Chin |
BUY
Grant, award, or other acquisition
|
Direct |
424
+3.11%
|
-
|
|
Mar 08
2024
|
Jonathan G Drachman |
BUY
Grant, award, or other acquisition
|
Direct |
415
+7.12%
|
-
|
|
Jan 07
2024
|
Julia Marie Eastland President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
178,500
+43.48%
|
-
|
|
Jan 07
2024
|
Frank J Lanza Principal Fin. & Acctng Ofc. |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+44.96%
|
-
|
|
Jan 07
2024
|
Luke Nathaniel Walker Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
115,000
+46.0%
|
-
|
|
Jan 01
2024
|
Mark Chin |
BUY
Grant, award, or other acquisition
|
Direct |
1,072
+7.73%
|
-
|
|
Jan 01
2024
|
Ronald Hunt |
BUY
Grant, award, or other acquisition
|
Direct |
1,072
+7.73%
|
-
|
|
Jan 01
2024
|
Scott Dunseth Myers |
BUY
Grant, award, or other acquisition
|
Direct |
2,048
+8.29%
|
-
|
|
Nov 27
2023
|
Jonathan G Drachman |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+50.0%
|
-
|
|
Nov 27
2023
|
Ronald Hunt |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+29.89%
|
-
|
|
Nov 27
2023
|
Scott Dunseth Myers |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+19.52%
|
-
|
|
Nov 27
2023
|
Andrew R Robbins |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+50.0%
|
-
|
|
Nov 27
2023
|
Lauren P Silvernail |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+50.0%
|
-
|
|
Nov 27
2023
|
Joseph S Bailes |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+50.0%
|
-
|
|
Nov 27
2023
|
Mark Chin |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+29.89%
|
-
|
|
Nov 26
2023
|
Julia Marie Eastland President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+48.31%
|
-
|
|
Nov 26
2023
|
Frank J Lanza Principal Fin. & Acctng Ofc. |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+37.3%
|
-
|
|
Nov 26
2023
|
Luke Nathaniel Walker Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+50.0%
|
-
|
|
Oct 25
2023
|
New Leaf Biopharma Opportunities Ii, L.P. |
BUY
Open market or private purchase
|
Indirect |
171,500
+30.23%
|
-
|
|
Oct 25
2023
|
New Leaf Biopharma Opportunities Ii, L.P. |
BUY
Open market or private purchase
|
Direct |
1,372,000
+48.39%
|
-
|
|
Oct 25
2023
|
Ronald Hunt |
BUY
Open market or private purchase
|
Indirect |
1,543,500
+39.31%
|
-
|
|
Oct 01
2023
|
Ronald Hunt |
BUY
Grant, award, or other acquisition
|
Direct |
3,035
+31.08%
|
-
|
|
Oct 01
2023
|
Scott Dunseth Myers |
BUY
Grant, award, or other acquisition
|
Direct |
5,797
+27.07%
|
-
|
|
Oct 01
2023
|
Mark Chin |
BUY
Grant, award, or other acquisition
|
Direct |
3,035
+31.08%
|
-
|
|
Jul 01
2023
|
Scott Dunseth Myers |
BUY
Grant, award, or other acquisition
|
Direct |
35,634
+26.62%
|
-
|
|
Jul 01
2023
|
Ronald Hunt |
BUY
Grant, award, or other acquisition
|
Direct |
18,656
+33.56%
|
-
|
|
Jul 01
2023
|
Mark Chin |
BUY
Grant, award, or other acquisition
|
Direct |
18,656
+33.56%
|
-
|
|
Apr 01
2023
|
Ronald Hunt |
BUY
Grant, award, or other acquisition
|
Direct |
18,285
+50.0%
|
-
|
|
Apr 01
2023
|
Scott Dunseth Myers |
BUY
Grant, award, or other acquisition
|
Direct |
34,925
+35.82%
|
-
|
|
Apr 01
2023
|
Joanne L. Viney Director |
BUY
Grant, award, or other acquisition
|
Direct |
21,028
+50.0%
|
-
|
|
Apr 01
2023
|
Mark Chin |
BUY
Grant, award, or other acquisition
|
Direct |
18,285
+50.0%
|
-
|
|
Apr 01
2023
|
Alan Colowick Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,456
+50.0%
|
-
|